Skip to main content
CBIOCrescent Biopharma, Inc.Sell6.3·$20.80+12.19%

Crescent Biopharma (CBIO) Q2 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+2.8% vs estimateEPS -$0.62 vs -$0.64 estCurrent verdict Sell 6.3/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
-$0.62
Estimate
-$0.64
Surprise
+2.8%
Score today
6.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Crescent Biopharma (CBIO) reported a narrower loss than forecast — diluted EPS of -$0.62 against the -$0.64 estimate (a 2.8% beat on a still-unprofitable quarter).

Current read · as of 2026-09-03

Where TrendMatrix's rating stands now

TrendMatrix currently rates CBIO Sell at 6.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +2.8% surprise compares with a -11.1% four-quarter average.

What argues against it

  • Concentration risk — Pipeline: CR-001, CR-002 and CR-003
  • Risk below floor (2.8 < 3.0)
  • Value-trap signals (2/5): Margin compression (op margin 0.2%), Material insider selling (12 sells, 0.41% of cap)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$20.80
Price target
$26.62
Stop
$18.97
Upside to target
+28.0%
Reward-to-risk
2.0:1

Risk check: trading volume is running 3.3× its average — elevated turnover around the report window.

Model outputs from TrendMatrix’s engine as of 2026-09-03 — shown for context, not personalized investment advice.

Healthcare context

CBIO at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$688.7M
P/E (fwd)
-7.0
52-week range
$8.72$27.41
Off 52-week high
24.1%
RSI (14)
66
Volume vs avg
3.34×
Score today
6.3/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks CBIO Earnings Q2 2026 earnings